KeyBanc analyst Matthew Mishan initiated coverage of Stryker with a Sector Weight rating and no price target. The company is a proxy for "high-quality MedTech," but its valuation reflects an above-average growth rate with some risk of mean reversion over time, the analyst tells investors in a research note. The firm sees Stryker’s size, competition, and the macro environment as potential limiting factors for upside to its long-term organic growth.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SYK:
- Stryker upgraded to Outperform from Sector Perform at RBC Capital
- Stryker price target raised to $265 from $257 at Barclays
- Stryker price target raised to $265, added to ‘TAP Outperform’ list at Evercore
- Hedge Funds Are Pouring Money into Stryker (NYSE:SYK) Stock
- Stryker to host conference call on January 31, 2023
